ProMetic Life Sciences Inc. is a Canada-based biopharmaceutical company. The Company is engaged in bioseparations, plasma-derived therapeutics and small-molecule drug development. The Company operates in two segments which include Protein Technologies and Therapeutics. In-house Therapeutics operating segment has lead compounds, namely PBI-4050 which target unmet medical needs such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. Protein Technology segments includes BioTherapeutics- The developer of a validated, state-of-the-art solution for plasma fractionation, the Plasma Protein Purification System; and Bioseparation-Develops and markets bioseparation products based on applications of its patented Mimetic Ligand technology; and Prion Capture/Pathogen Removal. The Company’s subsidiaries include ProMetic BioSciences Inc., ProMetic BioTherapeutics Inc. among others.